Navigation Links
The Natural-Hip Family - High Demand Porous (collared)

ProductsThe Natural-Hip Family - High Demand Porous (collared)
Company Zimmer, Inc.
Item The Natural-Hip Family - High Demand Porous (collared)
Features Innovative design combines the fit of an anatomic stem with the surgical ease of a straight stem, proximal geometry reduces risk of osteolysis, neck angle optimally restores natural anatomy of the hip, porous stem geometry reduces thigh pain and aids in rotational stability. The comprehensive Natural Hip Family offers a variety of stem options to address high, medium, and low demand patients, as well as revision and other special patient needs. This titanium stem has Cancellous-Structured Titanium (CSTiTM) mimics human cancellous bone, providing a reinforced flow barrier between the proximal area and the diaphysis, which may prevent osteolytic potential AND provides for biologic fixation.
Description The Natural-Hip combines the surgical simplicity of a straight stem with many of the best features of an anatomic stem.
Info Zimmer, Inc.
Customer Service: (800) 613-6131
Web site: http://www.zimmer.com

Related medicine products :

1. The Natural-Hip Family - Revision/Trauma Nonporous CoCr
2. The Natural-Hip Family - Revision/Trauma CoCr Revision
3. The Natural-Hip Family - Revision/Trauma Calcar
4. The Natural-Hip Family - High Demand Porous (collarless)
5. The Natural-Hip Family - High Demand Porous (short neck)
6. The Natural-Hip Family - Specialty Porous Collared HA
7. The Natural-Hip Family - Specialty Porous collarless HA
8. The Natural-Hip Family - Medium Demand Premier
9. The Natural-Hip Family - Low Demand (LD)
10. Surgicel Absorbable Hemostat Family
11. The APR Hip Family - CoCr Cemented
(Date:7/30/2015)... ... 30, 2015 , ... The Beryl Institute announces its sixth ... with Patient Experience Institute, these offerings reinforce the commitment to help frame and ... throughout the experience movement, and provide information and research to support expanded focus ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... as the company and UCLA’s Jonsson Comprehensive Cancer Center (JCCC) mutually ... With the new collaboration, OncLive’s editorial and marketing groups will help spread the ...
(Date:7/30/2015)... ... ... Ross A. Clevens, MD, FACS has been reappointed by the University ... This is Dr. Clevens’ second appointment by the prestigious school. Over the past ... and a valuable mentoring program for medical students. , The University ...
(Date:7/30/2015)... ... July 30, 2015 , ... Zejax ... New Tool That Increases Training Capability , World renown body weight trainer, ... ( http://www.Zejax.com ), that dramatically increases a person’s training capability. , The American ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... ... of the ‘Mary Jo Lawyer-Spano Mesothelioma Patient Registry Act of 2015’. The ... (D-IL), Chris Collins (R-NY), Peter King (R-NY), Betty McCollum (D-MN), Joe Kennedy (D-MA), ...
Breaking Medicine News(10 mins):Health News:The Beryl Institute Opens Applications for 2015 Patient Experience Grant and Scholar Programs 2Health News:The Beryl Institute Opens Applications for 2015 Patient Experience Grant and Scholar Programs 3Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 2Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 3Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 4Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 2Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 3Health News:Zejax is a Revolutionary New Way of BodyWeight Training Without Weights 2Health News:Bill to Create Patient Registry for Deadly Cancer Introduced in Congress 2
... 10 2007. A report to be published in an ... call for urgent attention to the politically sensitive issue of ... plans in the face of a catastrophic flu pandemic . ... transmission of a strain of avian influenza A (HN51) in ...
... Pharma US, Inc. today,announced results of an ... a prompt and sustained (over the 4-day,treatment ... among,hospitalized patients with euvolemic and hypervolemic hyponatremia ... correction. The study results were presented,during the ...
... in Council Bluffs, Now Offered to All Iowa ... ... Today, at the annual,conference of the Iowa State Police Association, ... Department,announced the availability of a community outreach program designed to,raise awareness ...
... Rat study suggests it boosts blood pressure, damages cells ... levels of lead exposure accelerated chronic kidney disease in ... kinds of cellular damage, U.S. researchers report. , Previous ... exposure and high blood pressure, atherosclerosis (hardening of the ...
... Gastrointestinal smooth muscle tumors (SMTs, including leiomyoma and ... to originate from a muscular layer of the ... esophagus, stomach, small intestine, and colon. SMTs are ... polyps, and complete surgical resection is still considered ...
... 10, 2007)--World Vaccine Congress: A first-in-man trial of a ... ADXS - News). The Phase I/II trial was testing ... is being developed by Advaxis as an immunotherapy that ... from human papilloma virus (HPV), including cervical cancer and ...
Cached Medicine News:Health News:Report highlights inadequate pandemic planning as a threat to EU security 2Health News:Data Show Vaprisol(R) Is Effective & Safe in Promptly Increasing Serum Sodium Levels in Patients With Euvolemic or Hypervolemic Hyponatremia 2Health News:Data Show Vaprisol(R) Is Effective & Safe in Promptly Increasing Serum Sodium Levels in Patients With Euvolemic or Hypervolemic Hyponatremia 3Health News:Data Show Vaprisol(R) Is Effective & Safe in Promptly Increasing Serum Sodium Levels in Patients With Euvolemic or Hypervolemic Hyponatremia 4Health News:Data Show Vaprisol(R) Is Effective & Safe in Promptly Increasing Serum Sodium Levels in Patients With Euvolemic or Hypervolemic Hyponatremia 5Health News:Partnership for a Drug-Free America and Council Bluffs Police Department Introduce Methamphetamine Prevention Program to Iowa Law Enforcement 2Health News:Partnership for a Drug-Free America and Council Bluffs Police Department Introduce Methamphetamine Prevention Program to Iowa Law Enforcement 3Health News:Advaxis, Inc. phase I/II results of lovaxin C in cervical cancer study released 2
(Date:7/30/2015)... , July 30, 2015 ... latest report titled, "Continuous Glucose Monitoring Systems Market: Global ... to the report, the global continuous glucose monitoring systems ... and is expected to reach US$ 788.4 Mn by ... period, 2015 to 2020. Global continuous glucose ...
(Date:7/30/2015)... July 30, 2015 ... report with market overview, trends, DRO analysis, ... analysis, recent developments, competitive scenario and top ... Insight: Biosensors Market Development and Demand Forecast ... http://photos.prnewswire.com/prnh/20150727/756778 ) Explore more about ...
(Date:7/30/2015)... July 30, 2015  Medimetriks Pharmaceuticals, Inc. announced ... Phase III clinical study for Ozenoxacin, a novel ... owns the exclusive U.S. rights to Ozenoxacin 1% ... at 44 centers with an emphasis on U.S. ... 2 months and older with a clinical diagnosis ...
Breaking Medicine Technology:Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 2Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 3Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 4Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 5Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3